This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

CSM recommendations

Authoring team

Prolonged use of cyproterone may produce dose-related hepatotoxicity. Effects include:

  • hepatitis
  • cholestatic jaundice
  • hepatic failure
  • death

The Committee on the Safety of Medicine recommend that:

  • long-term daily doses of 300 mg be restricted to:
    • short courses to cover the effects of LHRH agonists or following orchidectomy
    • patients who fail to respond to, or cannot tolerate, alternative treatments
  • liver function tests are conducted before treatment and whenever hepatic impairment is suspected
  • cyproterone is withheld once evidence of hepatotoxicity develops

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.